TY - JOUR T1 - Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 434 LP - 441 DO - 10.2967/jnumed.117.202945 VL - 59 IS - 3 AU - Jeremie Calais AU - Wolfgang P. Fendler AU - Matthias Eiber AU - Jeannine Gartmann AU - Fang-I Chu AU - Nicholas G. Nickols AU - Robert E. Reiter AU - Matthew B. Rettig AU - Leonard S. Marks AU - Thomas E. Ahlering AU - Linda M. Huynh AU - Roger Slavik AU - Pawan Gupta AU - Andrew Quon AU - Martin S. Allen-Auerbach AU - Johannes Czernin AU - Ken Herrmann Y1 - 2018/03/01 UR - http://jnm.snmjournals.org/content/59/3/434.abstract N2 - In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05–202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3–6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes. ER -